Pfizer releases vaccine data for 5-11 age group, affirms safety and efficacy
Pfizer today released the first data evaluating a COVID-19 vaccine’s safety and effectiveness for children between the ages of 5 and 11. The data, culled from a phase 2/3 trial, indicates that two, 10-microgram doses of Pfizer’s mRNA vaccine, administered 21 days apart, resulted in a strong immune response against SARS-CoV-2. Pfizer said the data would be included in a “near-term” application to the Food and Drug Administration for emergency use authorization in the 5-11 age group. The drug maker also indicated that it would soon have sufficient trial data for children under 5 for submission to FDA.
Related News Articles
Headline
The Department of Health and Human Services June 30 announced it will terminate emergency use authorization declarations for certain drugs and medical devices…
Headline
The Centers for Disease Control and Prevention Feb. 19 released a report on the low use of COVID-19 antiviral drugs among individuals age 65 and older, a…
Headline
The Centers for Disease Control and Prevention Dec. 11 released a report that found last year’s version of the COVID-19 vaccine was 76% effective in preventing…
Headline
The Advisory Committee on Immunization Practices Sept. 19 recommended that patients should consult their health care provider if they want to receive a COVID-…
Headline
The Food and Drug Administration July 10 approved Moderna’s Spikevax COVID-19 vaccine for children under 12 with at least one underlying condition that…
Headline
Department of Health and Human Services Secretary Robert F. Kennedy Jr. May 27 announced in a post on X that the Centers for Disease Control and Prevention…